Cargando…
Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab
INTRODUCTION: Treat-to-target strategies to achieve low disease activity or clinical remission are key in the treatment of rheumatoid arthritis (RA). 14-3-3η is a joint-derived biomarker that is expressed at significantly higher levels in patients with RA than in healthy subjects, other autoimmune d...
Autores principales: | Hirata, Shintaro, Marotta, Anthony, Gui, Yuan, Hanami, Kentaro, Tanaka, Yoshiya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599751/ https://www.ncbi.nlm.nih.gov/pubmed/26449724 http://dx.doi.org/10.1186/s13075-015-0799-7 |
Ejemplares similares
-
DAS28‐CRP Cutoffs for High Disease Activity and Remission Are Lower Than DAS28‐ESR in Rheumatoid Arthritis
por: Greenmyer, Jacob R., et al.
Publicado: (2020) -
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015) -
The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
por: Hirabayashi, Yasuhiko, et al.
Publicado: (2012) -
Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study
por: Lee, Yvonne C, et al.
Publicado: (2011) -
Response to 'Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study'
por: Yoshida, Kazuki, et al.
Publicado: (2011)